In PDA, an interesting approach to neutralize mutated KRAS was achieved by using a monoclonal antibody (mAb), RT11-i, for targeting the intracellular activated GTP-bound form of oncogenic RAS mutants [108]. The gene discussed is KRAS; the disease is Patent ductus arteriosus.